Effect of MGO on <i>in vitro</i> maturation and developmental competence of mouse COCs and DOs. by Shahrzad Ronasi (20933556)

The solvent accessible surface area (SASA) of wild-type (green line) AKR1C3 (complexed with the ligand, NADPH) was lower than that of the mutant (purple line) AKR1C3 (complexed wit... by Md. Akeruzzaman Shaon (21511929)

Subjects:

Hardy‒Weinberg equilibrium test of rs12529 in the study subjects. by Md. Akeruzzaman Shaon (21511929)

Subjects:

Demographic characteristics of the breast cancer patients enrolled in the study. by Md. Akeruzzaman Shaon (21511929)

Subjects:

FPRP values for the association between rs12529 and breast cancer risk. by Md. Akeruzzaman Shaon (21511929)

Subjects:

Representative restriction enzyme-digested products on a 2% agarose gel. by Md. Akeruzzaman Shaon (21511929)

Subjects:

Baseline characteristics of study subjects. by Md. Akeruzzaman Shaon (21511929)

Subjects:

The radius of gyration of wild-type and mutant (H5Q) AKR1C3 (both complexed with the ligand, NADPH). by Md. Akeruzzaman Shaon (21511929)

Subjects:

Functional effects of rs12529 (H5Q) on the AKR1C3 protein. by Md. Akeruzzaman Shaon (21511929)

Subjects:

The distribution of rs12529 (C15G) genotypes among participants categorized by menopausal status. by Md. Akeruzzaman Shaon (21511929)

Subjects:

Frequency distribution of rs12529 (C15G) genotypes in breast cancer patients and control subjects. by Md. Akeruzzaman Shaon (21511929)

Subjects:

The clinicopathological information of the patients involved in this study. by Md. Akeruzzaman Shaon (21511929)

Subjects:

Genotypic distribution of rs12529 in the study subjects. by Md. Akeruzzaman Shaon (21511929)

Subjects:

Distribution of rs12529 (C15G) genotypes in patients with different tumor grades. by Md. Akeruzzaman Shaon (21511929)

Subjects:

Distribution of rs12529 (C15G) genotypes in patients with different tumor sizes. by Md. Akeruzzaman Shaon (21511929)

Subjects:

Fig 4 - by Marjo K. Hytönen (8522271)

Segmented regression analysis of time to intravenous antimicrobial administration (IVA) at intervention and control sites during the implementation period. by J Mark Ansermino (13958512)

Subjects:

Interrupted time series analysis showing time to intravenous antimicrobials (IVA) in minutes at intervention and control sites in Uganda during baseline and implementation periods. by J Mark Ansermino (13958512)

Subjects:

Kenya: Enrolment, time to IVA, mortality, admissions and readmissions at sites in Kenya. by J Mark Ansermino (13958512)

Subjects:

Uganda: enrolment, time to IVA, mortality, admissions and readmissions. by J Mark Ansermino (13958512)

Subjects: